Fig 1: Prediction of RFS using the E2F-related gene signature of PCa patients in the MSKCC cohort. The distribution of risk scores (A) and disease statuses (B) in PCa patients, and the dashed line represents the median value of the risk score. The heatmap showed that the four identified genes, CDKN2C, CDKN3, RACGAP1, and RRM2, were highly expressed in PCa patients with high-risk scores compared to patients with low-risk scores (C), and patients with higher risk scores exhibited poorer RFS (D). The ROC curve analysis indicated the good performance of the E2F-related gene signature in RFS prediction (E), and the 1-, 3-, 5-, and 10-year time-dependent ROC curves indicated the good predictive value of the E2F-related gene signature (F)
Fig 2: Functional validation of CDKN2C and RACGAP1 in PCa cells. Immunohistochemistry analysis showed that CDKN2C and RACGAP1 were more significantly upregulated in PCa patients with Gleason score >7 and pathology stage III compared to patients with Gleason score =7 and pathology stage II (A, B). Western blotting and bar graph show the expression and densitometric of CDKN2C and RACGAP1 knockdown in PC3 cells (C, D) and C4-2 cells (E–F). MTT (G–H) and colony formation assays (I–L) revealed that the proliferation and colony formation abilities of PC3 and C4-2 cells were significantly suppressed in response to the knockdown of CDKN2C and RACGAP1
Fig 3: Protein expression levels and percentage of positivity for the three genes in clinical samples. (A) DSG2. (B) LDHA. (C) RACGAP1.
Fig 4: Establishment of an E2F-related RFS predictive gene signature using LASSO Cox regression in the MSKCC cohort. LASSO Cox regression identified four E2F-related genes, CDKN2C, CDKN3, RACGAP1, and RRM2, and the E2F-related gene signature was established based on these four genes (A, B). Based on the median expression levels of CDKN2C, CDKN3, RACGAP1, and RRM2, PCa patients were divided into high and low groups, and PCa patients with high expression levels of these four genes exhibited poorer recurrence-free survival time validated by log-rank survival test (C–F)
Supplier Page from Abcam for Anti-RACGAP1/MGCRACGAP antibody [EPR9018]